Summit Therapeutics (SMMT) Enterprise Value (2017 - 2026)

Summit Therapeutics (SMMT) has 10 years of Enterprise Value data on file, last reported at -$690.7 million in Q2 2026.

• Quarterly Enterprise Value fell 131.62% year-over-year to -$690.7 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$690.7 million (down 131.62% YoY) and the FY2025 annual result came in at -$713.4 million, down 73.02% from the prior year.
• Enterprise Value retreated to -$690.7 million in Q2 2026, from -$598.7 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$28.8 million in Q2 2024 to a low of -$713.4 million in Q4 2025.
• A 5-year average of -$302.9 million and a median of -$226.9 million in 2023 frame the typical range for Enterprise Value.
• Annual changes were most pronounced in 2023 — Enterprise Value jumped 88.99% — and 2025, when it sank 937.04%.
• Tracing SMMT's Enterprise Value over 5 years: stood at -$648.6 million in 2022, then jumped by 88.99% to -$71.4 million in 2023, then plunged by 477.32% to -$412.3 million in 2024, then sank by 73.02% to -$713.4 million in 2025, then rose by 3.19% to -$690.7 million in 2026.
• The last three Enterprise Value figures came in at -$690.7 million (Q2 2026), -$598.7 million (Q1 2026), and -$713.4 million (Q4 2025), per Business Quant data.